Status: Recruiting
Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH)
This clinical trial will evaluate whether combination therapy with Dapagliflozin + Macitentan improves outcomes compared to Dapagliflozin + placebo in patients with combined pre- and post-capillary pulmonary hypertension (CpcPH). The study will measure changes in pulmonary vascular resistance, NT-proBNP, 6-minute walk distance, and quality of life (KCCQ scores) over 24 weeks. Participants will be randomly assigned to one of two groups, take study medication for 24 weeks, and undergo regular clinical, laboratory, and safety assessments.
Participants needed: 64
Trial details
Phase: Phase 4Age: 19+Biological sex: AllType: InterventionalSponsor: Gachon University Gil Medical CenterUpdated: Apr 3, 2026Locations: 15
Eligibility criteria
A male or female adults aged 19 years or older in South Korea [+11]
Known hypersensitivity to the active ingredients (Macitentan, Dapagliflozin) or... [+26]